Protocols
CHUGAI-SPK101JG Phase I OPEN TO ACCRUAL
A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 as Monotherapy in Patients with Locally Advanced or Metastatic Solid Tumors
HOFFMANN-BO41932-TAPISTRY Phase II OPEN TO ACCRUAL
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
HOOKIPA-H-200-001 Phase I/II OPEN TO ACCRUAL
A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers
IIT-GORE-REDIRICT Phase II OPEN TO ACCRUAL
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)
INHIBRX-PH1-INBRX-106 Phase I/II OPEN TO ACCRUAL *
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors
MABSPACE-TST001-1001 Phase I/II OPEN TO ACCRUAL
A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination with Nivolumab or Standard of Care in Patients with Locally Advanced or Metastatic Solid Tumors
MERCK-MK1084-001 Phase I OPEN TO ACCRUAL
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRAS G12C Mutant Advanced Solid Tumors
MIRATI-1719-001 Phase I/II OPEN TO ACCRUAL
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
VMONCOLOGY-VMO-01C Phase I OPEN TO ACCRUAL
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma
XENCOR-XMAB808-01 Phase I OPEN TO ACCRUAL
A Phase 1, First-in-human (FIH), Dose-finding and Expansion Study to Evaluate the Safety and Tolerability of XmAb808 in Combination with Pembrolizumab in Selected Advanced Solid Tumors